Earlier prostate-specific antigen testing in African American men-Clinical support for the recommendation

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 7, 2015, Pages 330.e9-330.e17

  Saltzman, Amanda F ^a   Luo, Suhong ^b,c   Scherrer, Jeffery F ^b,d   Carson, Kenneth D ^b,c   Grubb, Robert L ^b,c   Hudson, M'Liss A ^b,e  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Diagnostic Clinic of Longview   (United States)

Author keywords

African American men; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; VETERAN; BIOPSY; BLOOD; CAUCASIAN; EARLY CANCER DIAGNOSIS; ETHNOLOGY; MIDDLE AGED; PROCEDURES; PROSTATE; PROSTATE TUMOR; REGISTER; SURGERY;

ADULT; AFRICAN AMERICANS; AGED; BIOPSY; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; VETERANS;

EID: 84930577073     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.03.018     Document Type: Article

References (39)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Talcott J.A., Spain P., Clark J.A., et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 2007, 109:1599-1606.
3. Shavers V.L., Brown M.L. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002, 94:334-357.
4. Klein J.B., Nguyen C.T., Saffore L., Modlin C., Modlin C.S. Racial disparities in urologic health care. J Natl Med Assoc 2010, 102:108-117.
5. Underwood W., Jackson J., Wei J.T., et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 2005, 103:538-545.
6. Schwartz K., Powell I.J., Underwood W., George J., Yee C., Bannerjee M. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009, 74:1296-1302.
7. Chornokur G., Dalton K., Borysova M.E., Kumar N.B. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011, 71:985-997.
8. Freedland S.J., Sutter M.E., Naitoh J., Dorey F., Csathy G.S., Aronson W.J. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology 2000, 55:387-390.
9. Giri V.N., Ruth K., Hughes L., et al. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. BJU Int 2011, 107:466-470.
10. Polednak A.P. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Nat Med Assoc 1998, 90:101-104.
11. Powell I.J., Banerjee M., Sakr W., et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men?. Cancer 1999, 85:472-477.
12. Wolf A.M., Wender R.C., Etzioni R.B., American Cancer Society Prostate Cancer Advisory Committee, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60:70-98.
13. Greene K.L., Albertsen P.C., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182:2232-2241.
14. Hudson M.A., Luo S., Chrusciel T., et al. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?. Urol Oncol 2014, 32:34.e9-34.e18.
15. Centers for Disease Control and Prevention. International Classification of Diseases. Ninth Revision; Clinical Modification, [accessed 23.09.14.]. http://www.cdc.gov/nchs/icd/icd9cm.htm.
16. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L., ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
17. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
18. International Union against Cancer TNM Classification of Malignant Tumours 2002, Wiley-Liss, New York, NY. 6th ed. L.H. Sobin, C.H. Wittekind (Eds.).
19. NCCN Clinical Practice Guidelines for Oncology: Prostate cancer, 2012 [accessed 1609.14. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
20. Romano P.S., Roos L.L., Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46:1075-1079.
21. DeSantis C., Naishadham D., Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin 2013, 63:151-166.
22. Unequal Treatment: Confronting Racial and Ethnic Disparities In Health Care 2002, The National Academies Press, Washington, DC. B.D. Smedley, A.Y. Stith, A.R. Nelson (Eds.).
23. Bianco F.J., Wood D.P., Cher M.L., Powell I.J., Souza J.W., Pontes J.E. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003, 1:242-247.
24. Makarov D.V., Sanderson H., Partin A., Epstein J. Gleason score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference of Gleason Scores 43 and 34 Independent of the Number of Involved Cores?. J Urol 2002, 167:2440-2442.
25. Amin A., Partin A., Epstein Gleason score 7 on needle biopsy: relation of primary 3 or 4 to pathologic stage and progression after radical prostatectomy. J Urol 2011, 186:1286-1290.
26. Laverty H.J., Droller M.J. Do Gleason patterns 4 and 3 prostate cancer represent different disease states?. J Urol 2012 Nov, 188:1667-1675.
27. Fanning D.M., Kay E., Fan Y., Fitzpatrick J.M., Watson R.W. Prostate cancer grading: the effect of stratification of needle biopsyGleason Score 4+3 as high or intermediate grade. BJU Int 2010, 105:631-635.
28. Vora A., Large T., Aronica J., Haynes S., Harbin A., Marchalik D., et al. Predictors of Gleason score upgrading in a largeAfrican-Americanpopulation. Int Urol Nephrol 2013, 45:1257-1262.
29. Powell I.J., Vigneau F.D., Bock C.H., Ruterbusch J., Heilbrun L.K. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev 2014, 23:1505-1511.
30. Sanchez-Ortiz R.F., Troncoso P., Babaian R.J., Lloreta J., Johnston D.A., Pettaway C.A. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 2006, 107:75-82.
31. Faisal F.A., Sundi D., Cooper J.L., Humphreys E.B., Partin A.W., Han M., et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology 2014, 84:1434-1441.
32. Dall[U+05F3]Era M.A., Albertsen P.C., Bangma C., et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012, 62:976-983.
33. Sundi D., Ross A.E., Humphreys E.B., et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?. J Clin Oncol 2013, 31:2991-2997.
34. Silberstein J.L., Feibus A.H., Maddox M.M., Abdel-Mageed A.B., Moparty K., Thomas R., et al. Active surveillance of prostate cancer in African American men. Urology 2014, 84:1255-1261.
35. Scherrer J.F., Chrusciel T., Zeringue A., et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. Am Heart J 2010, 159:772-779.
36. Andriole G.L., Crawford E.D., Grubb R.L., PLCO Project Team, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:125-132.
37. Schroder F.H., Hugosson J., Roobol M.J., ERSPC Investigators, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366:981-990.
38. Moyer V.A., U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157:120-134.
39. SEER Cancer Statistics Review 1975-2007, Prostate Cancer, [accessed 01.02.15.]. http://seer.cancer.gov/archive/csr/1975_2007/results_merged/sect_23_prostate.pdf.